JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Impact of Strength and Power Training on Golf Performance and Swing Biomechanics

  NCT04004468

  Conditions:   Resistance Training With Traditional Periodization Model;   Resistance Training With Conjugate Training Model
  Intervention:   Behavioral: Resistance Training
  Sponsor:   Methodist University, North Carolina
  Recruiting
• Palbociclib in Real World Practice

  NCT03280303

  Conditions:   Advanced Breast Cancer;   Metastatic Breast Cancer
  Intervention:   Other: non-interventional
  Sponsor:   Pfizer
  Recruiting
• Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome

  NCT03951077

  Condition:   Polycystic Ovary Syndrome
  Interventions:   Drug: Elagolix;   Drug: Placebo
  Sponsor:   AbbVie
  Recruiting
• A Phase 2b Study of Icosabutate in Fatty Liver Disease

  NCT04052516

  Condition:   Non Alcoholic Steatohepatitis (NASH)
  Interventions:   Drug: Icosabutate;   Drug: Placebo
  Sponsor:   NorthSea Therapeutics B.V.
  Recruiting
• A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause

  NCT04003389

  Condition:   Hot Flashes
  Interventions:   Drug: fezolinetant;   Drug: placebo
  Sponsor:   Astellas Pharma Global Development, Inc.
  Recruiting
• A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause

  NCT04003155

  Condition:   Hot Flashes
  Interventions:   Drug: fezolinetant;   Drug: placebo
  Sponsor:   Astellas Pharma Global Development, Inc.
  Recruiting
• A Phase 2b Study of NGM282 in Participants With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

  NCT03912532

  Condition:   NASH - Nonalcoholic Steatohepatitis
  Interventions:   Biological: NGM282;   Other: Placebo
  Sponsor:   NGM Biopharmaceuticals, Inc
  Recruiting
• Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

  NCT03902080

  Condition:   Overactive Bladder
  Interventions:   Drug: Vibegron;   Drug: Placebo
  Sponsor:   Urovant Sciences GmbH
  Recruiting
• Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

  NCT03888066

  Condition:   Hyperkalemia
  Interventions:   Drug: Patiromer;   Drug: Placebos
  Sponsors:   Relypsa, Inc.;   Vifor Pharma
  Recruiting
• Diabetic Gastroparesis Study 05

  NCT03786380

  Condition:   Gastroparesis
  Intervention:   Drug: Relamorelin 10 μg
  Sponsor:   Allergan
  Recruiting
• Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain

  NCT03692403

  Condition:   Endometriosis-related Pain
  Interventions:   Drug: Quinagolide 360 µg;   Drug: Quinagolide 720 µg;   Drug: Quinagolide 1080 µg;   Drug: Placebo
  Sponsor:   Ferring Pharmaceuticals
  Recruiting
• A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

  NCT03656744

  Conditions:   Fatty Liver, Nonalcoholic;   NAFLD;   Nonalcoholic Fatty Liver Disease;   Nonalcoholic Steatohepatitis;   Digestive System Diseases
  Interventions:   Drug: HTD1801;   Drug: Placebo
  Sponsor:   HighTide Biopharma Pty Ltd
  Recruiting
• Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

  NCT03578081

  Condition:   Malignant Neoplasm
  Interventions:   Drug: Palonosetron Hydrochloride;   Drug: Ondansetron Hydrochloride;   Drug: Dexamethasone;   Drug: Fosaprepitant Dimeglumine;   Drug: Olanzapine;   Other: Placebo
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis

  NCT03544229

  Conditions:   Diabetic Gastroparesis;   Idiopathic Gastroparesis
  Interventions:   Drug: TAK-906 Maleate;   Drug: TAK-906 Maleate Placebo
  Sponsor:   Millennium Pharmaceuticals, Inc.
  Recruiting
• A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE )

  NCT03518034

  Conditions:   Hypogonadism;   Cardiovascular Diseases
  Interventions:   Drug: Testosterone;   Drug: Placebo
  Sponsors:   AbbVie;   Acerus Pharmaceuticals Corporation;   Allergan Sales, LLC;   Endo Pharmaceuticals;   Upsher-Smith Laboratories
  Recruiting
• A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT03466411

  Condition:   Crohn's Disease
  Interventions:   Drug: Guselkumab Dose 1;   Drug: Guselkumab Dose 2;   Drug: Guselkumab Dose 3;   Drug: Guselkumab Dose 4;   Drug: Guselkumab Dose 5;   Drug: Guselkumab;   Drug: Ustekinumab;   Drug: Placebo
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)

  NCT03373045

  Condition:   Asthma
  Intervention:  
  Sponsors:   AstraZeneca;   Parexel;   MedImmune LLC
  Recruiting
• A POC and Dose-Ranging Study of HTD1801 in PSC Patients

  NCT03333928

  Condition:   Primary Sclerosing Cholangitis (PSC)
  Interventions:   Drug: HTD1801;   Drug: Placebo
  Sponsor:   HighTide Biopharma Pty Ltd
  Recruiting
• BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence

  NCT03320850

  Conditions:   Urinary Incontinence;   Overactive Bladder With Urinary Incontinence
  Interventions:   Drug: OnabotulinumtoxinA and Hydrogel admixture;   Drug: Placebo and Hydrogel admixture
  Sponsor:   Allergan
  Recruiting
• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01

  NCT03285308

  Conditions:   Gastroparesis;   Diabetes Mellitus
  Interventions:   Drug: Relamorelin;   Drug: Placebo
  Sponsor:   Allergan
  Recruiting
• Electronic Patient Reporting of Symptoms During Cancer Treatment

  NCT03249090

  Conditions:   Advanced Cancer;   Metastatic Cancer
  Interventions:   Other: Patient Self-Reporting of Symptoms;   Other: Usual Care Delivery
  Sponsors:   Alliance Foundation Trials, LLC.;   Patient-Centered Outcomes Research Institute;   University of North Carolina;   Mayo Clinic;   American Society of Clinical Oncology;   American Cancer Society, Inc.;   Dana-Farber Cancer Institute
  Recruiting
• Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men

  NCT03198728

  Condition:   Hypogonadism, Male
  Interventions:   Drug: SOV2012-F1;   Drug: AndroGel
  Sponsors:   Marius Pharmaceuticals;   Syneos Health
  Recruiting
• AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH

  NCT03028740

  Condition:   Nonalcoholic Steatohepatitis
  Interventions:   Drug: Cenicriviroc;   Drug: Placebo
  Sponsor:   Tobira Therapeutics, Inc.
  Recruiting
• Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS

  NCT02926911

  Conditions:   DCIS;   Ductal Carcinoma in Situ
  Interventions:   Other: Guideline Concordant Care;   Other: Active Surveillance
  Sponsors:   Alliance Foundation Trials, LLC.;   Patient-Centered Outcomes Research Institute;   Duke University;   Dana-Farber Cancer Institute;   M.D. Anderson Cancer Center;   New York University;   Washington University School of Medicine
  Recruiting
• Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144

  NCT02403323

  Condition:   Crohn Disease
  Intervention:   Drug: etrolizumab
  Sponsor:   Hoffmann-La Roche
  Recruiting
• A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD)

  NCT02394028

  Condition:   Crohn Disease
  Interventions:   Drug: Etrolizumab;   Drug: Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Integrated Cancer Repository for Cancer Research

  NCT02012699

  Conditions:   Pancreatic Cancer;   Thyroid Cancer;   Lung Cancer;   Esophageal Cancer;   Thymus Cancer;   Colon Cancer;   Rectal Cancer;   GIST;   Anal Cancer;   Bile Duct Cancer;   Duodenal Cancer;   Gallbladder Cancer;   Gastric Cancer;   Liver Cancer;   Small Intestine Cancer;   Peritoneal Surface Malignancies;   Familial Adenomatous Polyposis;   Lynch Syndrome;   Bladder Cancer;   Kidney Cancer;   Penile Cancer;   Prostate Cancer;   Testicular Cancer;   Ureter Cancer;   Urethral Cancer;   Hypopharyngeal Cancer;   Laryngeal Cancer;   Lip Cancer;   Oral Cavity Cancer;   Nasopharyngeal Cancer;   Oropharyngeal Cancer;   Paranasal Sinus Cancer;   Nasal Cavity Cancer;   Salivary Gland Cancer;   Skin Cancer;   CNS Tumor;   CNS Cancer;   Mesothelioma;   Breast Cancer;   Leukemia;   Melanoma;   Sarcoma;   Unknown Primary Tumor;   Multiple Myeloma;   Ovarian Cancer;   Endometrial Cancer;   Vaginal Cancer;   Neuroendocrine Tumors;   Plasma Cell Dyscrasia;   Healthy Control
  Intervention:  
  Sponsor:   University of Nebraska
  Recruiting
• International Hernia Mesh Registry

  NCT00622583

  Condition:   Hernia
  Intervention:  
  Sponsor:   Ethicon, Inc.
  Recruiting
• Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms

  NCT00443274

  Condition:   Breast Implant
  Interventions:   Other: NBIR Placeholder;   Device: 410 Arm;   Device: BIFs
  Sponsor:   Allergan
  Recruiting
• Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis

  NCT03987620

  Condition:   Candida Vulvovaginitis
  Interventions:   Drug: Ibrexafungerp;   Drug: Placebo
  Sponsors:   Scynexis, Inc.;   PPD
  Recruiting
• A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis

  NCT03935217

  Condition:   Trichomonas Infection
  Interventions:   Drug: Secnidazole;   Drug: Placebo
  Sponsor:   Lupin Research Inc
  Recruiting
• A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

  NCT03381196

  Condition:   Influenza A
  Interventions:   Drug: Pimodivir 600 mg;   Drug: Placebo;   Other: SOC Treatment
  Sponsor:   Janssen Research & Development, LLC
  Recruiting